Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zanubrutinib + sonrotoclax
- Development stage
- Phase 1
- Lead developer
- BeOne Medicines
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BG-71332 is a fixed-dose combination (FDC) tablet containing zanubrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, and sonrotoclax (BGB-11417), a B-cell lymphoma 2 (BCL2) inhibitor. Developed by BeiGene (under the affiliate BeOne Medicines), this combination aims to provide synergistic activity in B-cell malignancies by simultaneously targeting the BCR signaling pathway and the intrinsic apoptosis pathway. The FDC formulation is designed to improve patient convenience and adherence compared to co-administration of the individual agents. It is currently being evaluated in clinical trials for its pharmacokinetic profile, bioavailability, and food effect.
- Other names
- zanubrutinib/sonrotoclax FDCzanubrutinib and sonrotoclax fixed-dose combination
02
Targets
BCL-2 (BCL-2 family)BTK (Bruton tyrosine kinase)
Beyond the preview
Go deeper on zanubrutinib + sonrotoclax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zanubrutinib + sonrotoclax.